Expertise in
10
conditions

Dr. Safi G. Shahda

Internal Medicine
Office
535 Barnhill Dr Rm 473, 
Indianapolis, IN 
Accepting New Patients
Expertise in
10
conditions
Office
535 Barnhill Dr Rm 473, 
Indianapolis, IN 

Overview

Safi Shahda is a primary care provider, practicing in Internal Medicine in Indianapolis, Indiana.

Dr. Shahda is highly rated in 10 conditions, according to our data. His clinical expertise encompasses Familial Colorectal Cancer, Pancreatic Ductal Adenocarcinoma, Muscle Invasive Bladder Cancer, Non-Muscle Invasive Bladder Cancer, and Pancreaticoduodenectomy.

He is actively involved in clinical research, co-authoring 38 peer reviewed articles and participating in 9 clinical trials. Dr. Shahda is currently accepting new patients.

Specialties

Internal Medicine

Licenses

Internal Medicine in IN

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

CareSource
  • HMO
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D

Locations

Office
535 Barnhill Dr Rm 473, Indianapolis, IN 46202

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

Colorectal Cancer Metastatic dMMR/MSI-H Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab/Atezolizumab Combination Versus Single Agent Atezolizumab in the First-Line Treatment of Patients With Deficient DNA Mismatch Repair (dMMR)/Microsatellite Instability-High (MSI-H) Metastatic Colorectal Cancer
Colorectal Cancer Metastatic dMMR/MSI-H Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab/Atezolizumab Combination Versus Single Agent Atezolizumab in the First-Line Treatment of Patients With Deficient DNA Mismatch Repair (dMMR)/Microsatellite Instability-High (MSI-H) Metastatic Colorectal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: September 08, 2026
Intervention Type: Other, Procedure, Drug, Biological
Study Phase: Phase 3
A Randomized Phase III Study of Nivolumab After Combined Modality Therapy (CMT) in High Risk Anal Cancer
A Randomized Phase III Study of Nivolumab After Combined Modality Therapy (CMT) in High Risk Anal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Procedure, Biological, Other
Study Drug: Nivolumab
Study Phase: Phase 3
A Phase 1, Open-Label, Dose-Escalation and Expansion, Safety and Tolerability Study of INCB062079 in Subjects With Advanced Hepatocellular Carcinoma and Other Malignancies
A Phase 1, Open-Label, Dose-Escalation and Expansion, Safety and Tolerability Study of INCB062079 in Subjects With Advanced Hepatocellular Carcinoma and Other Malignancies
Enrollment Status: Terminated
Publish Date: October 21, 2025
Intervention Type: Drug
Study Phase: Phase 1
Phase II Multicenter Trial of Panitumumab, Nivolumab, and Ipilimumab for KRAS/NRAS/BRAF Wild-type MSS Refractory Metastatic Colorectal Adenocarcinoma
Phase II Multicenter Trial of Panitumumab, Nivolumab, and Ipilimumab for KRAS/NRAS/BRAF Wild-type MSS Refractory Metastatic Colorectal Adenocarcinoma
Enrollment Status: Completed
Publish Date: July 01, 2025
Intervention Type: Drug
Study Drugs: Panitumumab, Nivolumab, Ipilimumab
Study Phase: Phase 2
A Pilot Study of Pembrolizumab in Combination With Y90 Radioembolization in Subjects With Poor Prognosis Hepatocellular Carcinoma With Preserved Liver Function. HCRN: GI15-225
A Pilot Study of Pembrolizumab in Combination With Y90 Radioembolization in Subjects With Poor Prognosis Hepatocellular Carcinoma With Preserved Liver Function. HCRN: GI15-225
Enrollment Status: Unknown
Publish Date: February 06, 2023
Intervention Type: Drug, Device
Study Drug: Pembrolizumab
Study Phase: Early Phase 1
A Randomized Phase II Study of Perioperative mFOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel as Therapy for Resectable Pancreatic Adenocarcinoma
A Randomized Phase II Study of Perioperative mFOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel as Therapy for Resectable Pancreatic Adenocarcinoma
Enrollment Status: Completed
Publish Date: October 19, 2022
Intervention Type: Drug, Procedure
Study Drugs: Fluorouracil, Gemcitabine hydrochloride, Irinotecan hydrochloride, Oxaliplatin, Paclitaxel albumin-stabilized nanoparticle formulation
Study Phase: Phase 2
Phase I/IB Multi-center Study of Irreversible EGFR/HER2 Tyrosine Kinase Inhibitor Afatinib (BIBW 2992) in Combination With Capecitabine for Advanced Solid Tumors and Pancretico-Biliary Cancers
Phase I/IB Multi-center Study of Irreversible EGFR/HER2 Tyrosine Kinase Inhibitor Afatinib (BIBW 2992) in Combination With Capecitabine for Advanced Solid Tumors and Pancretico-Biliary Cancers
Enrollment Status: Completed
Publish Date: June 07, 2022
Intervention Type: Drug, Other
Study Drugs: Afatinib, Capecitabine
Study Phase: Phase 1
Preoperative Extended Chemotherapy vs. Chemotherapy Plus Hypofractionated Radiation Therapy for Borderline Resectable Adenocarcinoma of the Head of the Pancreas
Preoperative Extended Chemotherapy vs. Chemotherapy Plus Hypofractionated Radiation Therapy for Borderline Resectable Adenocarcinoma of the Head of the Pancreas
Enrollment Status: Unknown
Publish Date: May 24, 2022
Intervention Type: Drug, Procedure, Radiation
Study Drugs: mFOLFIRINOX, FOLFOX
Study Phase: Phase 2
A Phase II Study of Neoadjuvant FOLFIRINOX in Patients With Resectable Pancreatic Ductal Adenocarcinoma With Tissue Collection
A Phase II Study of Neoadjuvant FOLFIRINOX in Patients With Resectable Pancreatic Ductal Adenocarcinoma With Tissue Collection
Enrollment Status: Completed
Publish Date: April 19, 2022
Intervention Type: Drug
Study Drug: FOLFIRINOX
Study Phase: Phase 2
View 8 Less Clinical Trials

38 Total Publications

Nexiguran Ziclumeran Gene Editing in Hereditary ATTR with Polyneuropathy.
Nexiguran Ziclumeran Gene Editing in Hereditary ATTR with Polyneuropathy.
Journal: The New England journal of medicine
Published: September 26, 2025
Similar Doctors
Expertise in
12
conditions
Dr. Michael W. Weiner
Internal Medicine
Expertise in
12
conditions
Dr. Michael W. Weiner
Internal Medicine

Richard L. Roudebush Veterans Affairs Medical Center

1481 W 10th St, 
Indianapolis, IN 
 (1.3 miles away)
317-554-0000
Languages Spoken:
English
See accepted insurances

Michael Weiner is a primary care provider, practicing in Internal Medicine in Indianapolis, Indiana. Dr. Weiner is highly rated in 12 conditions, according to our data. His clinical expertise encompasses Alzheimer's Disease, Dementia, Developmental Dysphasia Familial, and Post-Traumatic Stress Disorder (PTSD).

Expertise in
13
conditions
Dr. Lee W. Mchenry
Internal Medicine
Expertise in
13
conditions
Dr. Lee W. Mchenry
Internal Medicine

Indiana University Health University Hospital

550 University Blvd, 
Indianapolis, IN 
 (0.9 miles away)
317-944-0980
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Lee Mchenry is a primary care provider, practicing in Internal Medicine in Indianapolis, Indiana. Dr. Mchenry is highly rated in 13 conditions, according to our data. His clinical expertise encompasses Biliary Dyskinesia, Sphincter of Oddi Dysfunction, Chronic Pancreatitis, Endoscopy, and Pancreaticoduodenectomy. Dr. Mchenry is currently accepting new patients.

Expertise in
7
conditions
Dr. Theodore F. Logan
Internal Medicine
Expertise in
7
conditions
Dr. Theodore F. Logan
Internal Medicine

Univ. Radiation Oncology Associates Inc.

535 Barnhill Dr, 
Indianapolis, IN 
 (1.0 miles away)
317-278-7576
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Theodore Logan is a primary care provider, practicing in Internal Medicine in Indianapolis, Indiana. Dr. Logan is highly rated in 7 conditions, according to our data. His clinical expertise encompasses Renal Cell Carcinoma (RCC), WT1-Related Wilms Tumor Syndromes, Chromophobe Renal Cell Carcinoma, Familial Wilms Tumor 2, and Lung Transplant. Dr. Logan is currently accepting new patients.

Frequently Asked Questions about Dr. Safi G. Shahda

How do I make an appointment with Dr. Safi G. Shahda?

You can book an appointment with Dr. Safi G. Shahda by calling their office at 317-274-5000. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Safi G. Shahda a top-rated expert for Familial Colorectal Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Safi G. Shahda is classified as an Distinguished expert for Familial Colorectal Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Safi G. Shahda specialize in?

While Dr. Safi G. Shahda is a Internal Medicine, they have specific expertise in Familial Colorectal Cancer, Pancreatic Ductal Adenocarcinoma, and Muscle Invasive Bladder Cancer. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Internal Medicine.

Does Dr. Safi G. Shahda participate in research or clinical trials?

Yes. Dr. Safi G. Shahda has published 38 articles and abstracts on conditions like Familial Colorectal Cancer. You can view a list of Dr. Safi G. Shahda's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Safi G. Shahda accept my insurance?

Dr. Safi G. Shahda accepts most major insurance plans, including CareSource and Medicare. We recommend calling the office directly at 317-274-5000 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Shahda's expertise for a condition
ConditionClose
    View All 8 Advanced Conditions
    View All 33 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile